Anti–TGF-β monoclonal antibodies 1D11, 2G7, lerdelimumab, metelimumab, and fresolimumab (GC1008) neutralize all three TGF-β isoforms and demonstrate significant antimetastatic activities in mouse models of breast cancer [19]. Here, TGFB1 is linked to breast cancer.